Arrakis Therapeutics, a biopharmaceutical company based in Massachusetts, announced earlier this week that it has agreed to a license agreement with Penn based on research developed by Prof. David Chenoweth and his research group in the area of small molecule drug candidates that directly target RNA. The license will allow utilization of technology related to families of compounds that selectively bind specific nucleic acid structures, called three-way junctions, that are present in folded RNA and have attractive characteristics for potential therapeutic targeting of RNA.
Read the full press release here.